PT1565463E - Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona - Google Patents

Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona Download PDF

Info

Publication number
PT1565463E
PT1565463E PT03767563T PT03767563T PT1565463E PT 1565463 E PT1565463 E PT 1565463E PT 03767563 T PT03767563 T PT 03767563T PT 03767563 T PT03767563 T PT 03767563T PT 1565463 E PT1565463 E PT 1565463E
Authority
PT
Portugal
Prior art keywords
compounds
formula
imidazo
methods
mediated diseases
Prior art date
Application number
PT03767563T
Other languages
English (en)
Portuguese (pt)
Inventor
Fariborz Firooznia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1565463E publication Critical patent/PT1565463E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03767563T 2002-11-18 2003-11-17 Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona PT1565463E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42732502P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
PT1565463E true PT1565463E (pt) 2008-09-10

Family

ID=32326521

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03767563T PT1565463E (pt) 2002-11-18 2003-11-17 Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona

Country Status (12)

Country Link
US (2) US7223866B2 (https=)
EP (1) EP1565463B1 (https=)
JP (1) JP2006508970A (https=)
CN (1) CN100447142C (https=)
AT (1) ATE398124T1 (https=)
AU (1) AU2003292039A1 (https=)
BR (1) BR0316306A (https=)
CA (1) CA2505752A1 (https=)
DE (1) DE60321593D1 (https=)
ES (1) ES2305520T3 (https=)
PT (1) PT1565463E (https=)
WO (1) WO2004046145A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052846A1 (en) * 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
DK1572632T3 (da) 2002-12-09 2008-10-27 Xention Ltd Tetrahydro-naphthalenderivater som vanilloidreceptorantagonister
WO2006092430A1 (de) * 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US7803810B2 (en) * 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
ES2448839T3 (es) 2007-11-01 2014-03-17 Bristol-Myers Squibb Company Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) * 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2013043518A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757884B1 (en) * 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Pyrazolopyridyl compounds as aldosterone synthase inhibitors
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
JO3137B1 (ar) 2012-01-17 2017-09-20 Novartis Ag أملاح وأشكال جديدة لمثبط إنزيم سينثاز أو أروماتاز ثنائي هيدروبيرولو [2،1-c] إيميدازوليل ألدوستيرون
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU24330B1 (es) 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75569C (fi) * 1981-06-22 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av terapeutiskt verkande imidazo/1,5-a/pyridiner.
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US5428160A (en) * 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
JPS615076A (ja) * 1984-06-19 1986-01-10 Toyama Chem Co Ltd 新規な１，４−ジヒドロピリジン誘導体およびその塩
GB8510541D0 (en) * 1985-04-25 1985-05-30 Wyeth John & Brother Ltd Heterocyclic compounds
US5798364A (en) * 1992-03-26 1998-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
DE19701257A1 (de) * 1997-01-17 1998-07-23 Hannecke Wolf D Kunststoff Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method

Also Published As

Publication number Publication date
AU2003292039A1 (en) 2004-06-15
ES2305520T3 (es) 2008-11-01
US20070197582A1 (en) 2007-08-23
BR0316306A (pt) 2005-09-27
DE60321593D1 (de) 2008-07-24
HK1081540A1 (en) 2006-05-19
US7713991B2 (en) 2010-05-11
CA2505752A1 (en) 2004-06-03
WO2004046145A1 (en) 2004-06-03
US20060058342A1 (en) 2006-03-16
CN1711262A (zh) 2005-12-21
EP1565463A1 (en) 2005-08-24
CN100447142C (zh) 2008-12-31
ATE398124T1 (de) 2008-07-15
JP2006508970A (ja) 2006-03-16
US7223866B2 (en) 2007-05-29
EP1565463B1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
PT1565463E (pt) Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona
EP1537114B8 (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
WO2008076336A3 (en) Imidazoles as aldosterone synthase inhibitors
WO2007117982A3 (en) Organic compounds
TNSN04126A1 (fr) 2-(pyridine-2-ylamino)-pyrido[2,3d] pyrimidine-7-ones
WO2007024945A8 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
WO2004100987A3 (en) Methods of using il-1 antagonists to treat neointimal hyperplasia
WO2009079412A3 (en) Reverse transcriptase inhibitors
GB2396864B (en) RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
MY121399A (en) Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1144373A3 (en) Serine protease inhibitors
WO2004020410A3 (en) Dihydropyridinone derivatives as hne inhibitors
WO2004052855A3 (en) Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005118824A3 (en) Methods and compositions for the inhibition of gene expression
UY25321A1 (es) Combinaciones de inhibidor de ace-inhibidor de mmp
PL1732534T3 (pl) Zastosowanie pochodnych amidowych metylenu przy zaburzeniach sercowo-naczyniowych
AU2001296821A1 (en) Methods of inhibiting angiogenesis using nadph oxidase inhibitors
ZA991922B (en) Novel compositions of eprosartan.
WO2006071644A8 (en) Selective inhibitors of erk protein kinases and uses therof
WO2003000183A3 (en) Method of treating atherosclerosis and other inflammatory diseases
NO20060247L (no) Substituerte spirobenzazepiner
DE60302344D1 (de) 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
ZA200609946B (en) Adamantyl-acetamide derivatives as inhibitor of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
TW200736264A (en) Thiazolo[4,5-C]pyridine derivatives